Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences

Rhea-AI Summary

Albireo Pharma (Nasdaq: ALBO), a clinical-stage biopharmaceutical company specializing in rare liver diseases, announced that CEO Ron Cooper will present at the Jefferies London Healthcare Conference on November 19, 2020, at 12 p.m. EST. The company is also participating in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3. A live audio webcast will be available on Albireo's Media & Investors page and archived for two weeks. Albireo focuses on novel bile acid modulators, with its lead product, odevixibat, in Phase 3 trials for pediatric cholestatic liver diseases.

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies London Healthcare Conference on November 19 at 12 p.m. EST. The Company will also be participating in the virtual Piper Sandler 32nd Annual Healthcare Conference being held December 1-3.

A live audio webcast of the Jefferies presentation will be accessible from the Albireo Media & Investors page (http://ir.albireopharma.com/) and will be archived and available for replay on Albireo’s website for two weeks following the event.

About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. The Company expects to complete IND-enabling studies for new preclinical candidate A3907 this year. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

Media & Investor contacts:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Hans Vitzthum, LifeSci Advisors, LLC., 857-272-6177

FAQ

When is Albireo Pharma's presentation at the Jefferies London Healthcare Conference?

Albireo Pharma's presentation is scheduled for November 19, 2020, at 12 p.m. EST.

How can I access the webcast of the Albireo Pharma presentation?

The webcast can be accessed via Albireo's Media & Investors page and will be archived for two weeks after the event.

What is the focus of Albireo Pharma's research and development?

Albireo Pharma develops novel bile acid modulators to treat rare pediatric and adult liver diseases.

What is the status of Albireo's lead product candidate, odevixibat?

Odevixibat is in Phase 3 development for rare pediatric cholestatic liver diseases.

What conferences is Albireo Pharma participating in besides the Jefferies Conference?

Albireo Pharma will also participate in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020.